Historical patterns indicate that abrupt fluctuations in the market can impact any firm, regardless of its seeming dominance.

Pfizer (PFE) stock dips as the company projects a revenue decline for 2026 amid a nearly $1.5B impact attributed to patent cliffs. Read more here.

Is Pfizer stock a buy at under 9x earnings? Yes. It is.

The pharmaceutical giant reaffirmed the modest 2026 outlook that rattled investors in December.

Pfizer's long-acting GLP-1 weight loss candidate could set the stage for a stock rally.

For Q3 FY26, Pfizer reported a net profit of Rs 141.8 crore, up 11.1 per cent year-on-year (YoY), compared with Rs 127.6 ...

Pfizer reported a quarterly loss Tuesday following a large write-down, denting shares as it confirmed 2026 financial targets with lower revenues. "Current financial guidance does not anticipate any ...

Pfizer India's shares surged after reporting strong Q3FY26 results, with net profit up 11% and revenue by 20%. The company ...

Pfizer posted adjusted earnings of 66 cents per share, beating the 57 cents forecast by analysts, News.Az reports, citing foreign ...

Analysts expect Pfizer’s revenue to decrease approximately 5% to around $16.95 billion, while adjusted earnings per share are projected to fall 9.5% to 57 cents compared to 63 cents in the same period ...

Pfizer Inc. remains a Strong Buy, offering compelling value with a 6.32% dividend yield and a P/E Non-GAAP of 8.43. Learn ...

The stock has been fairly stable over the past year.